Agios Pharmaceuticals, Inc.
AGIO· Nasdaq
AGIOAgios Pharmaceuticals, Inc.
Filed Feb 15, 2024 · 10-K · 46 days after period end · 0001439222-24-000035
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021 | Q4 2020 |
|---|---|---|---|---|
| Revenue | $7.10M | $4.31M | $0.00 | $44.05M |
| Net Income | -$95.94M | $36.53M | -$94.63M | -$97.66M |
| EPS Diluted | — | — | -$1.74 | -$1.41 |
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2023 · filed Feb 15, 2024 · 46 d after period end
